These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11738121)

  • 21. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of patient adherence to antiretroviral therapy on CD4+ cell count, HIV-1 RNA, and serum concentrations of tumor necrosis factor and its soluble receptors.
    Girón-González JA; López-Sánchez A; Elvira J; Perez E; Fernández-Gutiérrez C
    Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):852-8. PubMed ID: 11152310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
    Kim S; Hughes MD; Hammer SM; Jackson JB; DeGruttola V; Katzenstein DA
    AIDS Res Hum Retroviruses; 2000 May; 16(7):645-53. PubMed ID: 10791875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
    Ruane PJ; Richmond GJ; DeJesus E; Hill-Zabala CE; Danehower SC; Liao Q; Johnson J; Shaefer MS;
    Pharmacotherapy; 2004 Mar; 24(3):307-12. PubMed ID: 15040643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
    Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children.
    Purswani M; Johann-Liang R; Cervia J; Noel GJ
    Pediatr Infect Dis J; 1999 Jun; 18(6):512-6. PubMed ID: 10391180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The "induction-maintenance" strategy].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():8-11. PubMed ID: 19572438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
    Flandre P
    AIDS; 1999 Feb; 13(3):430-1. PubMed ID: 10199241
    [No Abstract]   [Full Text] [Related]  

  • 32. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.
    Gianotti N; Mondino V; Rossi MC; Chiesa E; Mezzaroma I; Ladisa N; Guaraldi G; Torti C; Tarquini P; Castelli P; Di Carlo A; Boeri E; Keulen W; Kenna PM; Lazzarin A;
    Clin Infect Dis; 2006 May; 42(10):1470-80. PubMed ID: 16619162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
    Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
    AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
    Katzenstein DA; Hughes M; Albrecht M; Hammer S; Para M; Murphy R; Valdez H; Haubrich R; Liou S
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1031-7. PubMed ID: 10933617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
    Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
    AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.